

PERSONAL INFORMATION



Corrado Barbui, MD

📍 Section of Psychiatry, Ospedale Policlinico GB Rossi, Piazzale Scuro 10, Verona, Italy

☎ +39 045 812 6418

✉ corrado.barbui@univr.it

Sex Male | Date of birth 13/02/1969 | Nationality Italian

CV OVERVIEW

Corrado Barbui holds an MD degree from the University of Milan and a postdoctoral degree in Psychiatry from the University of Verona. He received training in epidemiology, clinical psychopharmacology and health services research at the Mario Negri Institute for Pharmacological Research, Milan, Italy. He received additional training at the Institute of Psychiatry in London, where he joined the Editorial team of the Cochrane Collaboration Depression Anxiety & Neuroses Group.

Returning to Italy, he conducted research in the field of evidence-based mental health and pharmacoepidemiology under the leadership of Professor Michele Tansella. In 2013 he became Director of the WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation of the University of Verona. In 2015 he was appointed Full Professor of Psychiatry. Corrado Barbui founded in 2017 Cochrane Global Mental Health, a Cochrane network that supports the production, dissemination and implementation of systematic reviews relevant to mental health in low- and middle-income countries. He is also Editor-in-Chief of Epidemiology and Psychiatric Sciences, a Cambridge University Press Journal.

Corrado Barbui published so far over 350 scientific articles in international peer-reviewed journals, including papers in the Lancet, BMJ, JAMA, PLOS Medicine, World Psychiatry, JAMA Psychiatry, Lancet Psychiatry. A list of Professor Corrado Barbui scientific contributions can be accessed at: <http://scholar.google.it/citations?user=xloo8tMAAAAJ>

CURRENT POSITION

- 2015 – Present **Full Professor of Psychiatry**
University of Verona, Italy
- 2013 – Present **Director, WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation**
University of Verona, Italy

WORK EXPERIENCE

- 2012 – Present **Clinical Team Leader**
Azienda Ospedaliera Universitaria Integrata di Verona, Italy
- 2011 – 2014 **Associate Professor of Psychiatry**
University of Verona, Italy
- 2002 – 2010 **Lecturer in Psychiatry**
University of Verona, Italy

2000 – 2001 **Researcher**

Head, Laboratory of Epidemiology and Social Psychiatry, Mario Negri Institute for Pharmacological Research, Milan, Italy

1998-1999 **Visiting Scholar**

Section of Epidemiology and General Practice, Institute of Psychiatry, King's College, London, UK

EDUCATION AND TRAINING

2000 Qualification as Psychiatrist

1997 Qualification as Specialist in Pharmacological Research, Mario Negri Institute for Pharmacological Research, Milan, Italy

1993 Qualification as Medical Doctor (MD).

ADDITIONAL INFORMATION

2017 – Present **Coordinator**, Cochrane Global Mental Health - Cochrane Collaboration (<https://www.cochrane.org>)

2015 – Present **Editor-in-Chief**, *Epidemiology and Psychiatric Sciences* (<http://journals.cambridge.org/action/displayJournal?jid=EPS>)

2013 – Present Inclusion in the list of the Top Italian Scientists – based on the h-index score (<http://www.topitalianscientists.org>)

2002 – Present **Editor**, Cochrane Common Mental Disorders (CMD) Group - Cochrane Collaboration (<https://www.cochrane.org>)

INSTITUTIONAL ACTIVITIES

2018 – Present **President**, Commissione per il rispetto del Codice Etico dell'Università degli Studi di Verona (<http://www.univr.it/statuto-e-regolamenti>)

2018 – Present **Member**, CARU – Comitato di Approvazione per la Ricerca sull'Uomo – Università di Verona

SCIENTIFIC OUTPUT

Publications Professor Corrado Barbui published so far **over 350 full papers** in international scientific Journals. A list of Professor Corrado Barbui scientific contributions can be accessed at: <http://scholar.google.it/citations?user=xloo8tMAAAJ>

h-index (GOOGLE SCHOLAR): 60 (lifetime); 41 (last five years)

Citations (GOOGLE SCHOLAR): 15608 (lifetime); 9072 (last five years)

i10-index (GOOGLE SCHOLAR): 212 (lifetime); 145 (last five years)

Selection of 5 Publications

Cuijpers P, Karyotaki E, Reijnders M, Purgato M, Barbui C. Psychotherapies for depression in low- and middle-income countries: a meta-analysis. *World Psychiatry*, 17, 90-101, 2018.

Purgato M, Gross AL, Betancourt T, Bolton P, Bonetto C, Gastaldon C, Gordon J, O'Callaghan P, Papola D, Peltonen K, Punamaki RL, Richards J, Staples JK, Unterhitzberger J, van Ommeren M, de Jong J, Jordans MJD, Tol WA, Barbui C. Focused psychosocial interventions for children in low-resource humanitarian settings: a systematic review and individual participant data meta-analysis. *Lancet Global Health*, 6(4): e390-e400, 2018.

Barbui C, Bighelli I. Regulatory science in Europe: the case of schizophrenia trials. *Lancet*, 382, 1234-1235, 2013.

Barbui C, Dua T, van Ommeren M, Yasamy MT, Fleischmann A, Clark N, Thornicroft G, Hill S, Saxena S. Challenges in Developing Evidence-Based Recommendations Using the GRADE Approach: The Case of Mental, Neurological, and Substance Use Disorders. *PLOS Medicine*, 7, e1000322, 2010.

Reid S, Barbui C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. *BMJ*, 340, c1468-1472, 2010.

Book Chapters

Saraceno B, Terzian E, Montero-Barquero F, Tognoni G, Barbui C. Salud mental en el nivel primario de atención: Estudio en una muestra de pacientes en seis países centroamericanos. *Organización Panamericana de La Salud*, World Health Organisation, 1995.

Cipriani A, Barbui C, Baethge C, Wilder H, Geddes J. Antidepressive Monotherapie. In: Bauer M, Berghofer A, Adli M (eds). *Akute und Therapieresistente Depressionen*. Pringer Verlag: Heidelberg, pages 185-193, 2005.

Barbui C, Cipriani A, Tansella M. Beneficial and Adverse Effects of Antidepressants on Suicide Mortality in Individuals with Major Depression. In: *Suicide in Psychiatric Disorders*. Editors: R. Tatarelli, M. Pompili, P. Girardi. In press. Nova Science Publishers, Inc; 19-36, 2007.

Barbui C, Tansella M. La identificación y tratamiento de la enfermedad mental en atención primaria: el caso de la depresión. In *Psiquiatría en Atención Primaria*, 2nd Ed. (ed. J.L. Vazquez-Barquero), Aula Medica Ediciones: Madrid, 809-819, 2007.

Cipriani A, Barbui C. Understanding and using systematic literature reviews. In: *Oxford Textbook of Community Mental Health*. Eds: G Thornicroft, G Szmukler, KT Mueser, RE Drake. Oxford University Press: 2011.

Cipriani A, Nosè M, Barbui C. (2013) "Psychotropic drug epidemiology and systematic reviews of randomised clinical trials: The roads travelled, the roads ahead" in *Improving Mental Health Care: The Global Challenge*, Graham Thornicroft, Mirella Ruggeri, David Goldberg, ed Wiley-Blackwell, pag 319-340

Books

Martini N, Bonati M, Pandolfini C, Raschitelli N, Rossi LM, Farina LM, Bacis G, Grandori L, Zanfi D, Miselli M, Rocchi F, Barbui C, Bianchi M, Chiodini B, D'Avanzo B, Damia G, Martinoli E, Monesi L, Riva E, Roncaglioni MC, Schiavetti B, Clavenna A, Latini R, Nobili A, Zuccato E. *Guida all'uso dei farmaci per i bambini*. Ministero della Salute, Direzione Generale della Valutazione dei Medicinali e della Farmacovigilanza. Istituto Poligrafico e Zecca dello Stato S.p.A. Roma: 2003.

Barbui C, Cipriani A, Saxena S. *Pharmacological treatment of mental disorders in primary health care*. WHO Press, 2009. World health Organization, Geneva.

Barbui C, Bighelli I, Nosè M, Ostuzzi G, Purgato M e Gruppo di Lavoro del Dipartimento Interaziendale di Salute Mentale Verona *Uso degli Psicofarmaci in Situazioni Cliniche Complesse. Raccomandazioni GRADE* (2014). Il Pensiero Scientifico Editore: Roma, 2014.

Barbui C, Dua T, World Health Organization, Calouste Gulbenkian Foundation. *Improving access to and appropriate use of medicines for mental disorders*. Geneva: World Health Organization; 2017.

- Selected Grants**
- 1996 - Consiglio Nazionale delle Ricerche, Roma, Grant n. 201.12.78, Codice n. 12.00.41: Progetto Finalizzato “*Invecchiamento e Qualità della Vita, Aspetti Epidemiologici e Meccanismi Patogenetici*”.
- 1997 - Agreement for Performance of Work, World Health Organisation (WHO). GL GLO MNH 042 VP 96.999: ‘*The Rational Use of Psychotropic Drugs*’.
- 2001 - Agreement for Performance of Work, World Health Organisation (WHO) GL GLO MNH 348 XE 00.J: ‘*Improving Access to Essential Psychotropic Drugs in Developing Countries*’. WHO Geneva Switzerland.
- 2003 - Agreement for Performance of Work, World Health Organisation (WHO) GLGLOMNH166XK02: “*ATLAS – Psychotropics: improving psychotropic drug availability in the world*”. WHO Geneva Switzerland.
- 2003 - Ministero della Salute, Direzione Generale della Valutazione dei Medicinali e della Farmacovigilanza, Roma: “*Monitoraggio delle prescrizioni di farmaci antipsicotici e antidepressivi nell’attività territoriale e ospedaliera dei servizi psichiatrici*”.
- 2006 - Sperimentazione Multicentrica Nazionale Randomizzata denominata Studio LAST-RD: “*Lithium And Standard Therapy in Resistant Depression. An independent, pragmatic, multicentre, parallel-group, superiority trial*”.
- 2010 - Cochrane review of implementation of treatment guidelines for specialist mental health care. Ammesso al finanziamento sulla base di bando competitivo: Federal Ministry of Education and Research, Grant number 01KG1109, Germany.
- 2011 - Systematic Review of Meta-Analyses on the Efficacy of SSRI and SNRI in the Treatment of Major Depression. Ammesso al finanziamento sulla base di bando competitivo: Federal Ministry of Education and Research, Grant number 01KG0722, Germany.
- 2011 - Agreement for Performance of Work, World Health Organisation (WHO): To assist the WHO Secretariat in updating the mhGAP Evidence Resource Centre, within WHO mental health Gap Action Programme (mhGAP). WHO Geneva Switzerland. WHO Registration 2011/182038-0.
- 2013 - European Commission - Marie Curie International Outgoing Fellowship: 626466 CHILD TRAUMA IN LMIC FP7-PEOPLE-2013-IOF.
- 2014 - Agreement for Performance of Work, World Health Organisation (WHO): To assist WHO secretariat in updating mhGAP Evidence Resource Centre and Guidelines. WHO Geneva Switzerland. WHO Registration 2014/409411-0.
- 2014 - Agreement for Performance of Work, World Health Organisation (WHO): To assist WHO secretariat in developing the ETAT guidelines. WHO Geneva Switzerland. WHO Registration 2014/454490-0.
- 2016 - Call AIFA 2016: Assessing safety and efficacy of Vortioxetine versus SSRIs in elderly patients with depression: a pragmatic, multicenter, open-label, parallel-group, superiority, randomized trial (VESPA study: Vortioxetine in the Elderly vs. SSRIs: a Pragmatic Assessment).
- 2018 - European Union's Horizon 2020 Research and Innovation programme Societal Challenges under Grant Agreement No 779255: Refugee Emergency: DEFining and Implementing Novel Evidence-based psychosocial interventions – RE-DEFINE.

Last updated: August 2018